Telik is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs for the treatment of cancer and other serious diseases. Its most advanced development candidate is TELCYTA, a novel cancer cell-activated chemotherapeutic in trials for the treatment of advanced ovarian cancer and small cell lung cancer. The company has developed product candidates through the use of its proprietary TRAP technology, which enables the rapid and efficient discovery of small molecule drug candidates. In addition to its internal drug development programs, the company partners with select academic institutions and pharmaceutical biotechnology companies to apply TRAP to new drug development programs for a variety of diseases. Telik is located in Palo Alto, Calif.